HomeCompareMCQEF vs ABBV

MCQEF vs ABBV: Dividend Comparison 2026

MCQEF yields 3.46% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $78.8K in total portfolio value
10 years
MCQEF
MCQEF
● Live price
3.46%
Share price
$135.60
Annual div
$4.69
5Y div CAGR
-6.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.5K
Annual income
$218.36
Full MCQEF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MCQEF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMCQEFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MCQEF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MCQEF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MCQEF
Annual income on $10K today (after 15% tax)
$293.96/yr
After 10yr DRIP, annual income (after tax)
$185.61/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,870.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MCQEF + ABBV for your $10,000?

MCQEF: 50%ABBV: 50%
100% ABBV50/50100% MCQEF
Portfolio after 10yr
$62.9K
Annual income
$12,495.06/yr
Blended yield
19.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MCQEF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
0.6
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MCQEF buys
0
ABBV buys
0
No recent congressional trades found for MCQEF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMCQEFABBV
Forward yield3.46%3.06%
Annual dividend / share$4.69$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-6.1%40.6%
Portfolio after 10y$23.5K$102.3K
Annual income after 10y$218.36$24,771.77
Total dividends collected$2.7K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: MCQEF vs ABBV ($10,000, DRIP)

YearMCQEF PortfolioMCQEF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,025$324.74$11,550$430.00$525.00ABBV
2$12,111$314.19$13,472$627.96$1.4KABBV
3$13,261$302.88$15,906$926.08$2.6KABBV
4$14,481$291.05$19,071$1,382.55$4.6KABBV
5$15,773$278.90$23,302$2,095.81$7.5KABBV
6$17,144$266.60$29,150$3,237.93$12.0KABBV
7$18,598$254.30$37,536$5,121.41$18.9KABBV
8$20,142$242.09$50,079$8,338.38$29.9KABBV
9$21,782$230.09$69,753$14,065.80$48.0KABBV
10$23,525$218.36$102,337$24,771.77$78.8KABBV

MCQEF vs ABBV: Complete Analysis 2026

MCQEFStock

Macquarie Group Limited provides diversified financial services in Australia, the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through four segments: Macquarie Asset Management (MAM), Banking and Financial Services (BFS), Commodities and Global Markets (CGM), and Macquarie Capital. The MAM segment provides investment solutions to clients across various capabilities in private markets and public investments, including infrastructure, green investments, agriculture and natural assets, real estate, private credit, asset finance, equities, fixed income, and multi-asset solutions. The BFS segment offers personal banking products comprising home loans, car loans, transaction and savings accounts, and credit cards; and wrap platform and cash management, financial advisory, private banking, and stockbroking services, as well as investment and superannuation products. It also provides deposit, lending, and payment solutions and services to business clients, such as sole practitioners to corporate professional firms. The CGM segment provides risk management, lending and financing, capital solutions, market access, and physical execution and logistics to corporate and institutional clients; and specialist finance and asset management solutions. The Macquarie Capital segment provides advisory and capital raising services. It is also involved in facilitation, and development and investment in infrastructure and energy projects and companies; and trading of fixed income, equities, foreign exchange, and commodities, as well as provides broking services, corporate and structured finance, and leasing and underwriting services. Further, the company engages in the distribution and management of funds and wealth management products. Macquarie Group Limited was founded in 1969 and is headquartered in Sydney, Australia.

Full MCQEF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MCQEF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MCQEF vs SCHDMCQEF vs JEPIMCQEF vs OMCQEF vs KOMCQEF vs MAINMCQEF vs JNJMCQEF vs MRKMCQEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.